

REMARKS

This is in response to the Official Action dated 17 November 2006 in the referenced application.

Election

Applicant hereby elects species 2 (claims 2 and 5) directed to monoclonal antibody 4B6, with traverse. Claims 1 and 8 also encompass the elected species.

Applicant respectfully requests reconsideration of the conclusion in the office action that the species of the present invention do not relate to a single general inventive concept.

First, all of the monoclonal antibodies listed in Figures 1 and 2 function the same – each binds to GW 182. Secondly, the sequences listed in Figures 1 and 2, and therefore any monoclonal antibody produced to any of those sequences, are typically pooled when used in a detection regimen. Applicant has claimed at least two separate inventive concepts in the form of claim 1 and 8. As such, the species that form an aspect of Applicant's invention form a single general inventive concept. Reconsideration is respectfully requested.

Sequence Listing

The Office Action indicates that the application fails to comply with the sequence listing requirements, even though Applicant submitted all of this information to the International Bureau. In order to advance prosecution of the present application, a Sequence Listing has been submitted in a separate paper that has attached:

1. A paper copy of the Sequence Listing.
2. A diskette with a computer readable form of the Sequence Listing.

The content of the paper and computer readable copies are the same, and these submissions do not include matter that goes beyond the disclosure in the application as originally filed.

Claim amendment

The basis for the amendment to claim 8, changing diagnosis to detecting, can be found in paragraph 0021, among other places in the specification.

If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney at 301-203-6300 (a local call).

The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 02-4650.

Respectfully submitted,



December 18, 2006


William J. Bundren
PTO Reg. No. 31,712

734 Larue Road
Millersville, Maryland 21108-2155

Telephone: 410-923-2660
Facsimile: 410-923-2478

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service, on the date shown below, as Express Mail addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


William J. Bundren

18 DEC 2006
date